Kiniksa Pharmaceuticals International Plc

KNSANASDAQ · USD
76.08USD0.00 (-2.47%)
6310

Kiniksa Pharmaceuticals International Plc (KNSA) Straddle

KNSA straddle scan found 46 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 44.0%.

Read more

Trading a KNSA straddle lets you take a pure volatility position on Kiniksa Pharmaceuticals International Plc without committing to a direction. Kiniksa Pharmaceuticals International Plc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate KNSA straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on KNSA profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Kiniksa Pharmaceuticals International Plc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the KNSA straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the KNSA straddle is the cleanest expression of that view. Our scanner prices every KNSA straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a KNSA straddle into a catalyst or short a KNSA straddle to harvest decay, the options straddle setups that matter are all in one place.

Jan 15, 2027115.00$39.651202%44.0%$154.65$75.350
Apr 16, 2027115.00$42.302112%43.4%$157.30$72.700
Dec 18, 2026100.00$24.75922%43.3%$124.75$75.250
Dec 18, 202695.00$20.48922%43.2%$115.48$74.530
Dec 18, 2026105.00$29.60922%42.8%$134.60$75.400
Jan 15, 2027110.00$35.401202%42.6%$145.40$74.600
Apr 16, 2027110.00$38.252112%42.4%$148.25$71.750
Oct 16, 202685.00$9.25292%42.1%$94.25$75.750
Oct 16, 202675.00$8.10292%40.8%$83.10$66.9016
Apr 16, 2027105.00$34.902112%40.6%$139.90$70.100

As of September 23, 2026

Find the right straddle before volatility moves

Track KNSA straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.

Start your 14-day free trial